BR112020006316A2 - processo para preparar uma fração de lisado de plaquetas, fração de lisado de plaquetas e seu uso para tratar transtornos do sistema nervoso central - Google Patents
processo para preparar uma fração de lisado de plaquetas, fração de lisado de plaquetas e seu uso para tratar transtornos do sistema nervoso central Download PDFInfo
- Publication number
- BR112020006316A2 BR112020006316A2 BR112020006316-9A BR112020006316A BR112020006316A2 BR 112020006316 A2 BR112020006316 A2 BR 112020006316A2 BR 112020006316 A BR112020006316 A BR 112020006316A BR 112020006316 A2 BR112020006316 A2 BR 112020006316A2
- Authority
- BR
- Brazil
- Prior art keywords
- platelet lysate
- fraction
- platelet
- kda
- fact
- Prior art date
Links
- 239000006166 lysate Substances 0.000 title claims abstract description 214
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000008569 process Effects 0.000 title claims abstract description 18
- 208000015114 central nervous system disease Diseases 0.000 title claims description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 208000018737 Parkinson disease Diseases 0.000 claims description 13
- 210000003169 central nervous system Anatomy 0.000 claims description 13
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 230000007954 hypoxia Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 230000006931 brain damage Effects 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 3
- 208000017376 neurovascular disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 2
- 208000018642 Semantic dementia Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 238000007914 intraventricular administration Methods 0.000 claims description 2
- 210000000211 third ventricle Anatomy 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000001772 blood platelet Anatomy 0.000 description 205
- 210000004027 cell Anatomy 0.000 description 34
- 230000000324 neuroprotective effect Effects 0.000 description 30
- 239000003634 thrombocyte concentrate Substances 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 26
- BKQFRNYHFIQEKN-UHFFFAOYSA-N erastin Chemical compound CCOC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C(C)N1CCN(C(=O)COC=2C=CC(Cl)=CC=2)CC1 BKQFRNYHFIQEKN-UHFFFAOYSA-N 0.000 description 24
- 239000003981 vehicle Substances 0.000 description 24
- 230000037396 body weight Effects 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 16
- 210000002381 plasma Anatomy 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 102200064229 rs28937888 Human genes 0.000 description 13
- 101150062190 sod1 gene Proteins 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000004623 platelet-rich plasma Anatomy 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 230000034994 death Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 230000004112 neuroprotection Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 6
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000000185 intracerebroventricular administration Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000004766 neurogenesis Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 238000002617 apheresis Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940126638 Akt inhibitor Drugs 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000012574 advanced DMEM Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003186 pharmaceutical solution Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 241001451794 Cerus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004806 ferroptosis Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000001471 fibrinogenolytic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 102000052654 human GDNF Human genes 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036362 sensorimotor function Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306284.5 | 2017-09-27 | ||
| EP17306284 | 2017-09-27 | ||
| PCT/EP2018/076244 WO2019063683A1 (en) | 2017-09-27 | 2018-09-27 | PROCESS FOR THE PREPARATION OF PLATELET LYSATE FRACTION, PLATELET LYSATE FRACTION AND USE THEREOF FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020006316A2 true BR112020006316A2 (pt) | 2020-09-24 |
Family
ID=60083230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020006316-9A BR112020006316A2 (pt) | 2017-09-27 | 2018-09-27 | processo para preparar uma fração de lisado de plaquetas, fração de lisado de plaquetas e seu uso para tratar transtornos do sistema nervoso central |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230135837A1 (enExample) |
| EP (1) | EP3687554A1 (enExample) |
| JP (1) | JP2020535163A (enExample) |
| CN (1) | CN111107857A (enExample) |
| AU (1) | AU2018343875A1 (enExample) |
| BR (1) | BR112020006316A2 (enExample) |
| CA (1) | CA3076858A1 (enExample) |
| IL (1) | IL273482A (enExample) |
| RU (1) | RU2020112898A (enExample) |
| TW (1) | TW201914595A (enExample) |
| WO (1) | WO2019063683A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108671224B (zh) * | 2011-06-27 | 2022-12-13 | 爱默蕾大学 | 血小板裂解物的组合物、用途和制备 |
| TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
| US20210236556A1 (en) * | 2020-02-03 | 2021-08-05 | Oklahoma Blood Institute | Preparation of human platelet lysate (hpl) from refrigerated whole blood platelets |
| EP3881858A1 (en) * | 2020-03-20 | 2021-09-22 | Rok Pangersic | Heat-treated platelet-derived growth factor extract for use in a method of preventing or treating a tissue defect |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4815063B2 (ja) * | 2001-04-13 | 2011-11-16 | きみ子 室伏 | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤 |
| SE528214C2 (sv) * | 2005-06-23 | 2006-09-26 | Proliff Ab | Förfarande för framställning av blodplättslysat |
| EP2101806B1 (en) * | 2006-12-14 | 2013-05-01 | NeuroNova AB | Treatment of parkinson's disease or parkinsonian disorders using agents that decrease the activity of the melanocortin 4 receptor |
| EP2389942B1 (en) * | 2010-05-25 | 2013-01-23 | GwoWei Technology Co., Ltd. | Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof |
| US11285100B2 (en) * | 2014-02-20 | 2022-03-29 | Ortho Regenerative Technologies Inc. | Freeze-dried polymer compositions for mixing with platelet rich plasma to form implants for tissue repair and/or compositions for therapeutic intra-articular injections |
| CA3138143A1 (en) * | 2014-05-16 | 2015-11-19 | Mayo Foundation For Medical Education And Research | Cell culture media compositions for primary cells |
-
2018
- 2018-09-26 TW TW107133811A patent/TW201914595A/zh unknown
- 2018-09-27 CA CA3076858A patent/CA3076858A1/en active Pending
- 2018-09-27 JP JP2020517424A patent/JP2020535163A/ja active Pending
- 2018-09-27 US US16/650,070 patent/US20230135837A1/en not_active Abandoned
- 2018-09-27 EP EP18782679.7A patent/EP3687554A1/en not_active Withdrawn
- 2018-09-27 RU RU2020112898A patent/RU2020112898A/ru unknown
- 2018-09-27 BR BR112020006316-9A patent/BR112020006316A2/pt not_active IP Right Cessation
- 2018-09-27 AU AU2018343875A patent/AU2018343875A1/en not_active Abandoned
- 2018-09-27 WO PCT/EP2018/076244 patent/WO2019063683A1/en not_active Ceased
- 2018-09-27 CN CN201880061493.6A patent/CN111107857A/zh active Pending
-
2020
- 2020-03-22 IL IL273482A patent/IL273482A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201914595A (zh) | 2019-04-16 |
| AU2018343875A1 (en) | 2020-04-16 |
| RU2020112898A (ru) | 2021-10-04 |
| US20230135837A1 (en) | 2023-05-04 |
| JP2020535163A (ja) | 2020-12-03 |
| EP3687554A1 (en) | 2020-08-05 |
| IL273482A (en) | 2020-05-31 |
| WO2019063683A1 (en) | 2019-04-04 |
| CA3076858A1 (en) | 2019-04-04 |
| CN111107857A (zh) | 2020-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7370870B2 (ja) | プールヒト血小板溶解物を調製するための方法、プールヒト血小板溶解物、及び神経障害を処置するためのその使用 | |
| KR102805434B1 (ko) | 성장 인자들 함유 혈소판 방출물을 제조하는 방법 | |
| ES2639561T3 (es) | Procedimiento de preparación de un concentrado de factores de crecimiento derivado de plaquetas humanas | |
| JP6796143B2 (ja) | トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物 | |
| BR112020006316A2 (pt) | processo para preparar uma fração de lisado de plaquetas, fração de lisado de plaquetas e seu uso para tratar transtornos do sistema nervoso central | |
| AU2017238476B2 (en) | Preparation of platelet pellet lysate and its use for treating neurological disorders | |
| RU2802440C2 (ru) | Способ получения объединенного лизата тромбоцитов человека, объединенный лизат тромбоцитов человека и его применение для лечения неврологических нарушений | |
| WO2024110937A1 (en) | Compositions based on a mixture of bioactive molecules and exosomes for use in the treatment of conditions requiring tissue repair and regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2794 DE 23/07/2024. |